The effect of interferon and desferrioxamine on serum ferritin and hepatic iron concentrations in chronic hepatitis B

Hepato-Gastroenterology

Volumn 45, Issue 24, 1998, Pages 2322-2327

  Bayraktar, Yusuf ^a   Saglam, Fatma ^a   Temizer, Aytekin ^a   Uzunalimodlu, Bedri ^a   Van Thiel, David H ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Chronic viral hepatitis; Desferrioxamine; Ferritin; HBV; IFN therapy; Iron

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBODY; DEFEROXAMINE MESYLATE; FERRITIN; INTERFERON; IRON; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIETARY INTAKE; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS B; HUMAN; HUMAN TISSUE; LIVER LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION;

ADULT; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; IRON; LIVER; MALE; TREATMENT OUTCOME;

EID: 0032443440     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Lambiase L, Davis G: Treatment of chronic hepatitis. Gastroenterol Clinics of North America 1992; 21:663.
2. Naoumov NV, Thomas MG, Mason AL, Chokshi S, Bodicky CJ, Farzaneh F, Williams R, Perrillo RP: Genomic variations in the hepatitis B core gene: A possible factor influencing response to interferon alfa treatment. Gastroenterol 1995; 108:505-514.
3. Olynyk JK, Reddy KR, Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, Bacon BR: Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterol 1995; 108:1104-1109.
4. Scheuer PJ: Classification of chronic viral hepatitis: A need for reassessment. Journal of Hepatol 1991; 13:372-374.
5. Kreeftenberg HG, Koopman BJ, Huizenga JR, van Vilsteren T, Wolthers BG, Gips CH: Measurement of iron in liver biopsies - a comparison of three analytical methods. Clin Chim Acta 1984; 144:255-262.
6. Brissot P, Bourel M, Herry D, Verger JP, Messner M, Beaumont C, Regnouard F, Ferrand B, Simon M: Assessment of liver iron content in 271 patients: A reevaluation of direct and indirect methods. Gastroenterol 1981; 80:557-565.
7. DiBisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR: Measurement of iron status in patients with chronic hepatitis. Gastroenterol 1992; 102:2108-2113.
8. Badylack SF, Simmons A, Turek J, Babbs CF: Protection from reperfusion injury in the isolated rat heart by postischemic desferrioxamine and oxypurinal administration. Cardiovasc Res 1987; 21:500-506.
9. Van Der Kraaij AMM, van Eijk HG, Koster JF: Prevention of postischemic cardiac injury by the orally active iron chelator 1,2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidol-3. Circulation 1989; 80:158-164.
10. Lustbader ED, Hann HL, Blumberg HS: Serum ferritin as a predictor of host response to hepatitis B virus infection. Science 1983; 220:423-425.
11. Felton C, Lustbader ED, Merten C, Blumberg BS: Serum iron levels and response to hepatitis B virus. Proc Natl Acad Sci USA 1979; 76:2438-2441.
12. Piperno A, D'Alba R, Roffi L, Pozzi M, Farina A, Vecchi L, Fiorelli G: Hepatitis C virus infection in patients with idiopathic hemochromatosis (IH) and porphyria cutanea tarda (PCT). Arch Virol 1992; 4:215-216.
13. Fargion S, Piperno A, Cappellini MD, Sampietro M, Fracanzani AL, Romano R, Caldarelli R, Marcelli R, Vecchi L, Fiorelli G: Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association. Hepatol 1992; 16:1322-1326.
14. Litwin CM, Calderwood SB: Role of iron in regulation of virulence genes. Clin Microbiol Rev 1993; 6:137-138.
15. Byrd TF, Horwitz MA: Interferon gamma-activated human monocytes down regulate transferrin receptors and inhibit the intracellular multiplication of legionella pneumophila by limiting the availability of iron. J Clin Invest 1989; 83:1457-1465.
16. Silliman CC, Peterson VM, Mellman DL, Dixon DJ, Hambidge KM, Lane PA: Iron chelation by desferrioxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double blind study of the dose-response relationship. Journal of Lab Clin Med 1993; 122:48-54.
17. Olivieri NF, Berriman AM, Tyler BJ, David SA, Francombe WH, Liu PP: Reduction in tissue iron stores with a new regimen of continuous ambulatory intravenous desferrioxamine. Amer J Hematol 1992; 41:61-63.
18. Rocchi E, Cassanelli M, Borghi A, Paolillo F, Pradelli M, Pellizzardi S, Vezzosi A, Gallo E, Baccarani-Contri M, Ventura E: Liver iron overload and desferrioxamine treatment of porphyria cutanea tarda. Dermatologica 1991; 182:27-31.
19. Richardson ME, Matthews RN, Allison JF, Menahem S, Mitvalsky J, Byrt E, Harper RW: Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassemia major. Aust & NZ J of Med 1993; 23:656-661.
20. Mehta AM, Engstrom RE Jr, Kreiger AE: Desferrioxamine-associated retinopathy after subcutaneous injection (letter). Amer J of Opthal 1994; 118:260-262.
21. Koren G, Kochavi-Atiya Y, Bentur Y, Olivieri NF: The effects of subcutaneous desferrioxamine administration on renal function in thalassemia major. International J of Hematol 1991; 54:371-375.
22. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N, Logan W, Mitchell D, Ricci G, Skarf B: Visual and auditory neurotoxicity in patients receiving desferrioxamine infusions. N Eng J Med 1986; 314:869-873.
23. A study from Rennes, France, related to interferon treatment leads to a decrease in hepatic iron concentration in patients with chronic hepatitis C infection. Presented at the Fifth International Conference on Hemocromatosis, Boston, April, 1995.
24. Van Thiel DH, Friedlander L, Malloy P, Kania JK, Fagioli S, Wright HI, Gasbarrini A, Caraceni P: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-Gastroenterol 1996; 43:1557-1561.
25. Guptas RC, Mulhotra S, Lehandekar P: Influence of low iron diet on the efficacy of interferon therapy in patients with chronic liver disease. Proceedings of IX Bicennial Scientific Meeting Asian Pacific Association for the study of the liver. Kuala Lampur, Malaysia, January 26-29, 1994.
26. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. American Journal of Gastroenterol 1994; 89:986-989.